Q-omics provides the consensus-scored ZDHHC5 profile across patient tissues and cancer cell-line models. ZDHHC5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZDHHC5 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ZDHHC5 protein abundance shows 20,714 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where ZDHHC5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZDHHC5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZDHHC5 survival associations across molecular data types. ZDHHC5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZDHHC5 RNA expression–survival associations across cancer types. High ZDHHC5 expression shows unfavorable associations in UVM, ACC, BLCA, PAAD, LGG and KICH. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZDHHC5 RNA expression.
This table summarizes ZDHHC5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZDHHC5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZDHHC5 shows higher tumor expression in HNSC, LIHC, KIRP, LUSC, BLCA and LUAD. The HNSC box plot shows higher ZDHHC5 RNA expression in tumor versus normal tissue (log2 FC = +0.553, t-test p < 0.001).
This table shows molecular features associated with ZDHHC5 in patient tissues and cancer cell lines. In patient samples, ZDHHC5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZDHHC5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
